simvastatin + atorvastatin + pravastatin

Simvastatin, atorvastatin, and pravastatin are all members of the statin class (HMG-CoA reductase inhibitors), which are prescription drugs used to lower low-density lipoprotein (LDL) cholesterol and reduce cardiovascular risk. They act by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), a key enzyme in the cholesterol biosynthesis pathway in the liver. Simvastatin and atorvastatin are among the most effective statins for reducing LDL cholesterol levels, while pravastatin is noted for having fewer drug interactions due to its metabolism outside of cytochrome P450 3A4 pathways[1][2][8]. These agents are first-line treatments for hypercholesterolemia and prevention of atherosclerotic cardiovascular disease[2][4]. Developed by Merck (simvastatin) and Pfizer (atorvastatin).